SEC Form 4 · accession 0000884731-16-000075

ARIAD PHARMACEUTICALS INC · ARIA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Massimo Radaelli

Director

Period of report

Jun 10, 2016

Accepted (ET)

Jun 14, 2016 · 6:13 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000884731

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 10, 2016	M	22,588	$1.35	A	128,088	D
Common Stock	Jun 10, 2016	S	22,588	$8.30	D	105,500	D
Common Stock	Jun 13, 2016	M	27,319	$6.38	A	132,819	D
Common Stock	Jun 13, 2016	M	2,412	$1.35	A	135,231	D
Common Stock	Jun 13, 2016	M	25,000	$7.39	A	160,231	D
Common Stock	Jun 13, 2016	M	25,000	$6.45	A	185,231	D
Common Stock^F2	Jun 13, 2016	S	79,731	$8.2505	D	105,500	D
Common Stock	Jun 14, 2016	M	6,250	$4.91	A	111,750	D
Common Stock^F3	Jun 14, 2016	S	6,250	$8.1334	D	105,500	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4,F5	$1.35	Jun 10, 2016	M	22,588	D	Oct 10, 2009	Oct 10, 2018	Common Stock	22,588	2,412	D
Stock Option (Right to Buy)^F6,F5	$6.38	Jun 13, 2016	M	27,319	D	Jan 31, 2011	Jan 31, 2021	Common Stock	27,319	0	D
Stock Option (Right to Buy)^F4,F5	$1.35	Jun 13, 2016	M	2,412	D	Oct 10, 2009	Oct 10, 2018	Common Stock	2,412	0	D
Stock Option (Right to Buy)^F7,F5	$7.39	Jun 13, 2016	M	25,000	D	Mar 31, 2014	Jan 31, 2024	Common Stock	25,000	0	D
Stock Option (Right to Buy)^F8,F5	$6.45	Jun 13, 2016	M	25,000	D	Mar 31, 2015	Jan 31, 2025	Common Stock	25,000	0	D
Stock Option (Right to Buy)^F9,F5	$4.91	Jun 14, 2016	M	6,250	D	Mar 31, 2016	Feb 1, 2026	Common Stock	6,250	18,750	D

Explanation of responses

F1The shares were acquired and sold upon exercise of stock options that would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.2550, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.131 to $8.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
F4The stock options were granted on 10/10/2008 and vested in three annual installments commencing on 10/10/2009.
F5The stock options would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
F6The stock options were granted on 01/31/2011 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2011.
F7The stock options were granted on 01/31/2014 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2014.
F8The stock options were granted on 01/31/2015 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2015.
F9The stock options were granted on 02/01/2016 and vest as to one-fourth of the options in quarterly installments commencing on March 31, 2016.